Information Provided By:
Fly News Breaks for April 24, 2018
BIIB
Apr 24, 2018 | 15:22 EDT
Jefferies analyst Michael Yee lowered his price target for Biogen to $300 from $375, while reiterating a Hold rating on the shares, on a conservative multiple in current environment. The analyst notes that core multiple sclerosis franchise continues to be managed in face of adversity, but with Spinraza shifting to a more moderate growth trajectory, stock has been in range because focus is heightened on BD/M&A to provide growth without binary Alzheimer's and data is far out in 2020. Assuming or not assuming any M&A, Yee still sees a longer-term turnaround waiting for Alzheimer's data.
News For BIIB From the Last 2 Days
There are no results for your query BIIB